231 related articles for article (PubMed ID: 17350953)
1. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain.
Edwards SR; Wandless TJ
J Biol Chem; 2007 May; 282(18):13395-401. PubMed ID: 17350953
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor.
Bastidas RJ; Shertz CA; Lee SC; Heitman J; Cardenas ME
Eukaryot Cell; 2012 Mar; 11(3):270-81. PubMed ID: 22210828
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the FKBP.rapamycin.FRB ternary complex.
Banaszynski LA; Liu CW; Wandless TJ
J Am Chem Soc; 2005 Apr; 127(13):4715-21. PubMed ID: 15796538
[TBL] [Abstract][Full Text] [Related]
4. Saccharomyces cerevisiae FKBP12 binds Arabidopsis thaliana TOR and its expression in plants leads to rapamycin susceptibility.
Sormani R; Yao L; Menand B; Ennar N; Lecampion C; Meyer C; Robaglia C
BMC Plant Biol; 2007 Jun; 7():26. PubMed ID: 17543119
[TBL] [Abstract][Full Text] [Related]
5. The role of glycerol-water mixtures in the stability of FKBP12-rapalog-FRB complexes.
Lopez JJD; Gaza JT; Nellas RB
J Mol Graph Model; 2023 Nov; 124():108556. PubMed ID: 37423019
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity.
Bayle JH; Grimley JS; Stankunas K; Gestwicki JE; Wandless TJ; Crabtree GR
Chem Biol; 2006 Jan; 13(1):99-107. PubMed ID: 16426976
[TBL] [Abstract][Full Text] [Related]
7. An evaluation tool for FKBP12-dependent and -independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR.
Sekiguchi M; Kobashigawa Y; Kawasaki M; Yokochi M; Kiso T; Suzumura K; Mori K; Teramura T; Inagaki F
Protein Eng Des Sel; 2011 Nov; 24(11):811-7. PubMed ID: 21900305
[TBL] [Abstract][Full Text] [Related]
8. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR.
Veverka V; Crabbe T; Bird I; Lennie G; Muskett FW; Taylor RJ; Carr MD
Oncogene; 2008 Jan; 27(5):585-95. PubMed ID: 17684489
[TBL] [Abstract][Full Text] [Related]
9. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression.
Vilella-Bach M; Nuzzi P; Fang Y; Chen J
J Biol Chem; 1999 Feb; 274(7):4266-72. PubMed ID: 9933627
[TBL] [Abstract][Full Text] [Related]
10. Effect of FKBP12-Derived Intracellular Peptides on Rapamycin-Induced FKBP-FRB Interaction and Autophagy.
Parada CA; de Oliveira IP; Gewehr MCF; Machado-Neto JA; Lima K; Eichler RAS; Lopes LR; Bechara LRG; Ferreira JCB; Festuccia WT; Censoni L; Tersariol ILS; Ferro ES
Cells; 2022 Jan; 11(3):. PubMed ID: 35159195
[TBL] [Abstract][Full Text] [Related]
11. The FRB domain of mTOR: NMR solution structure and inhibitor design.
Leone M; Crowell KJ; Chen J; Jung D; Chiang GG; Sareth S; Abraham RT; Pellecchia M
Biochemistry; 2006 Aug; 45(34):10294-302. PubMed ID: 16922504
[TBL] [Abstract][Full Text] [Related]
12. In Silico Strategy for Targeting the mTOR Kinase at Rapamycin Binding Site by Small Molecules.
Vittorio S; Gitto R; Adornato I; Russo E; De Luca L
Molecules; 2021 Feb; 26(4):. PubMed ID: 33669763
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of purified recombinant mTOR FRB-kinase domain using fluorescence-based assays.
Reichling LJ; Lebakken CS; Riddle SM; Vedvik KL; Robers MB; Kopp LM; Bruinsma R; Vogel KW
J Biomol Screen; 2008 Mar; 13(3):238-44. PubMed ID: 18354135
[TBL] [Abstract][Full Text] [Related]
14. Rescue of degradation-prone mutants of the FK506-rapamycin binding (FRB) protein with chemical ligands.
Stankunas K; Bayle JH; Havranek JJ; Wandless TJ; Baker D; Crabtree GR; Gestwicki JE
Chembiochem; 2007 Jul; 8(10):1162-9. PubMed ID: 17525916
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR.
Cruz MC; Goldstein AL; Blankenship J; Del Poeta M; Perfect JR; McCusker JH; Bennani YL; Cardenas ME; Heitman J
Antimicrob Agents Chemother; 2001 Nov; 45(11):3162-70. PubMed ID: 11600372
[TBL] [Abstract][Full Text] [Related]
16. The pharmacology of mTOR inhibition.
Guertin DA; Sabatini DM
Sci Signal; 2009 Apr; 2(67):pe24. PubMed ID: 19383975
[TBL] [Abstract][Full Text] [Related]
17. The FKBP-rapamycin binding domain of human TOR undergoes strong conformational changes in the presence of membrane mimetics with and without the regulator phosphatidic acid.
Rodriguez Camargo DC; Link NM; Dames SA
Biochemistry; 2012 Jun; 51(24):4909-21. PubMed ID: 22620485
[TBL] [Abstract][Full Text] [Related]
18. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution.
Liang J; Choi J; Clardy J
Acta Crystallogr D Biol Crystallogr; 1999 Apr; 55(Pt 4):736-44. PubMed ID: 10089303
[TBL] [Abstract][Full Text] [Related]
19. Conditionally controlling nuclear trafficking in yeast by chemical-induced protein dimerization.
Xu T; Johnson CA; Gestwicki JE; Kumar A
Nat Protoc; 2010 Nov; 5(11):1831-43. PubMed ID: 21030958
[TBL] [Abstract][Full Text] [Related]
20. Large FK506-binding proteins shape the pharmacology of rapamycin.
März AM; Fabian AK; Kozany C; Bracher A; Hausch F
Mol Cell Biol; 2013 Apr; 33(7):1357-67. PubMed ID: 23358420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
